We’re thrilled to announce that the World Economic Forum (WEF) today named LunaPBC™, the public benefit corporation behind LunaDNA™, one of its newest Technology Pioneers — ahead of hundreds of up-and-coming tech companies, worldwide. This designation globally recognizes LunaPBC as a startup breaking health data barriers towards the goal of accelerating health discovery through people-powered research.

Medical breakthroughs and improving quality of life depend on comprehensive, continuous, real-world health data organized to support medical discovery. People are the best curators of their health data, and we need them as partners in research,” said Dawn Barry, president and co-founder, LunaPBC. “This model brings together social responsibility with technology for real-world, frictionless, passive information capture. We can imagine research as a continuous relationship versus a moment in time transaction.”

WEF was established in 1971 as an International Organization for Public-Private Cooperation, engaging the foremost political, business and other leaders of society to shape global, regional and industry agendas.

Since 2000, WEF established the Technology Pioneer community to recognize early to growth-stage companies from around the world that are making waves in the design, development, and deployment of new technologies and innovations, and are positioned to have a significant impact on the world. With this designation, LunaPBC joins acclaimed Technology Pioneers, including Wikimedia, Twitter, Spotify, Google and AirBnB.

LunaPBC is now immersed into WEF’s events and initiatives, where we’ll be at the center of cutting-edge insights and novel perspective in world-changing discussions. From July 1 to July 3, Bob Kain will be in Dalain, China, participating in the WEF Annual Meeting of the New Champions. There, he’ll be discussing the impact of ground-breaking genetics and molecular science related to human longevity in a session entitled, “What If: You Could Live to 150?”. Select awardees will also attend the January 2020 Annual Meeting in Davos, Switzerland to continue contributing to WEF initiatives over the next two years.

LunaPBC team from left to right: James White, Thomas Rodriguez, Debora Thompson, Kirby Bloom, David Lewis, Dawn Barry, Bob Kain, Scott Kahn, Alexandria Leonidova, Bojil Velinov, Mayank Tyagi, Genevieve Lopez
Bob Kain
Bob Kain, CEO + Co-founder at LunaPBC

This exciting news comes just one month after our funding announcement from top tier venture capitalists, including ARCH Venture Partners, Bain Capital Ventures, F-Prime Capital, Illumina Ventures, and Osage University Partners. A few months before, we proudly announced our strategic partnership with Genetic Alliance, the world’s leading nonprofit health advocacy group committed to transforming health research for individuals and communities.

We’re only halfway through  the year and together we’re already paving global paths in health research. WEF’s Technology Pioneer 2019 award is a reminder of the strides we’re making as a community directly contributing to health discovery. Thank you for being a part of this journey with us at LunaDNA.

About Luna

Luna’s suite of tools and services connects communities with researchers to accelerate health discoveries. With participation from more than 180 countries and communities advancing causes including disease-specific, public health, environmental, and emerging interests, Luna empowers these collectives to gather a wide range of data—health records, lived experience, disease history, genomics, and more—for research.

Luna gives academia and industry everything they need from engagement with study participants to data analysis across multiple modalities using a common data model. The platform is compliant with clinical regulatory requirements and international consumer data privacy laws.

By providing privacy-protected individuals a way to continually engage, Luna transforms the traditional patient-disconnected database into a dynamic, longitudinal discovery environment where researchers, industry, and community leaders can leverage a range of tools to surface insights and trends, study disease natural history and biomarkers, and enroll in clinical studies and trials.